Management of cardiovascular risk in systemic lupus erythematosus: a systematic review

• Published in: Lupus Vol. 26; no. 13; pp. 1407 - 1419
• Main Authors: Andrades, C, Fuego, C, Manrique-Arija, S, Fernández-Nebro, A
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.11.2017; Sage Publications Ltd
• Subjects: Anticoagulants; Antihypertensives; Antimalarials - therapeutic use; Arteriosclerosis; Blood pressure; Calcium (blood); Calories; Cardiovascular diseases; Cardiovascular Diseases - etiology; Cardiovascular Diseases - prevention & control; Cerebral infarction; Cholesterol; Coronary artery; Drugs; Exercise; Health Promotion; Health risk assessment; Humans; Hyperlipidemia; Hypolipidemic Agents - therapeutic use; Insulin; Lipids; Lipids - blood; Lipoproteins; Lupus; Lupus Erythematosus, Systemic - complications; Mortality; Myocardial infarction; Platelet Aggregation Inhibitors - therapeutic use; Risk Factors; Secondary Prevention; Serum levels; Systemic lupus erythematosus; cardiovascular events; Systemic lupus erythematosus; cardiovascular risk factors
• ISSN: 0961-2033; 1477-0962
• DOI: 10.1177/0961203317704710

Systemic lupus erythematosus is associated with accelerated atherosclerosis and increased risk of cardiovascular complications. The aim of this study was to review the effectiveness of interventions for primary and secondary prevention of cardiovascular events and mortality and to review the effectiveness of interventions for cardiovascular risk factor reduction in systemic lupus erythematosus patients. A systematic review was conducted. Electronic databases Medline and Embase (1961–2015) were searched. Nineteen articles met the inclusion criteria and were selected. Low-calorie and/or low glycaemic index calories may be a useful option for secondary prevention in obese patients with systemic lupus erythematosus, and exercise would be useful in improving the endothelial function measured by flow-mediated dilation in this group of patients. The use of lipid-lowering drugs may improve the lipid profile in patients with systemic lupus erythematosus and hyperlipidaemia, but the effect of this treatment on overall cardiovascular mortality remains unknown. Antiplatelets, anticoagulants, antimalarials and lipid-lowering drugs may be effective in the primary and secondary prevention of major cardiovascular events, such as acute myocardial infarction or stroke. Similarly, lipid-lowering drugs and antimalarial drugs appear to reduce the serum levels of total cholesterol, low-density lipoprotein, glucose, diastolic blood pressure and calcium deposition at the coronary arteries. They may also improve insulin resistance and the level of high-density lipoproteins. It appears that treatment with antihypertensive drugs reduces blood pressure in patients with systemic lupus erythematosus, but the available studies are of low quality.